Cardiovascular Clinical Studies

This channel includes news and new technology innovations from cardiovascular clinical trials. These clinical studies include all cardiac subspecialties.

$The WASE-COVID Study used the artificial intelligence automated echocardiogram reading software EchoGo-Core from Ultromics to evaluate ejection fraction and left ventricle longitudinal strain in COVID-19 patients to identify risk markers for mortality. The study also compared human vs. AI variability in assessing the exams. #ACC21 #ACC2021$

Feature | Coronavirus (COVID-19)

AI Derived Cardiac Echo Measurements Able to Predict COVID-19 Mortality

May 18, 2021 — Artificial intelligence (AI) derived heart measurements were able to predict COVID-19 (SARS-CoV-2) mortal ...

May 18, 2021

The results of the GALACTIC-HF trial shows omecamtiv mecarbil offers benefits to severe heart failure patients. #ACC21 #ACC2021 #GALACTICHF

News | Heart Failure

GALACTIC-HF Shows Omecamtiv Mecarbil Brings Greater Benefits for Severe Heart Failure

May 18, 2021 — The experimental heart failure drug omecamtiv mecarbil reduced heart failure hospitalizations by a ...

May 18, 2021

News | Coronavirus (COVID-19)

Dapagliflozin Did Not Significantly Reduce Organ Failure or Death in High-Risk Hospitalized COVID-19 Patients

May 18, 2021 — Dapagliflozin (Farxiga), a sodium-glucose co-transporter 2 (SGLT2) inhibitor, did not significantly ...

May 18, 2021

Videos | Robotic Systems

VIDEO: Robotic PCI Performed Well in Real-world Population in the PRECISION GRX Study

Ehtisham Mahmud, M.D., division chief of cardiovascular medicine, director of interventional cardiology and the cardiac ...

May 18, 2021

This trial used a therapeutic hypothermia system that used balloon catheters filled with cooled saline, such as the Zoll Thermogard XP temperature management system. #ACC21 #ACC2021 #therapeutichypothermia

News | Sudden Cardiac Arrest

Lower Temperature Therapeutic Hypothermia Did Not Improve Outcomes After Cardiac Arrest

May 17, 2021 — In patients receiving therapeutic hypothermia after suffering out-of-hospital cardiac arrest, those who ...

May 17, 2021

The anticoagulant rivaroxaban (Xarelto), in addition to low-dose aspirin, significantly reduced the occurrence of total severe events of the heart, limb or brain and issues related to other vascular complications in patients with symptomatic peripheral artery disease (PAD) who underwent lower extremity revascularization. The findings from the VOYAGER PAD trial were presented at the American College of Cardiology (ACC) 2021 Scientific Session.

News | Peripheral Artery Disease (PAD)

Rivaroxaban Reduces First and Total Ischemic Events in Patients with Peripheral Artery Disease

May 17, 2021 — The anticoagulant rivaroxaban (Xarelto), in addition to low-dose aspirin, significantly reduced the ...

May 17, 2021

The FLOWER-MI trial presented at ACC 2021 found no benefit to FFR-guided PCI in STEMI with multi-vessel disease. #ACC21 #ACC2021 #FFR

News | FFR Technologies

No Benefit to FFR-guided PCI in STEMI Patients With Multi-Vessel Disease

May 17, 2021 — In patients who received a coronary stent for an ST-elevation myocardial infarction (STEMI) heart attack ...

May 17, 2021

The Record Paradise RDN catheter uses a balloon catheter filled with water to cool the vessel wall as ultrasound-based ablation energy is delivered. It delivers a ring of ablative energy to a depth of 1-6 mm. Kirtane said it requires 2-3 sonications lasting 7 seconds each in each of the main renal arteries. #ACC21 #ACC2021 #RDN

Feature | Hypertension | By Dave Fornell, Editor

Renal Denervation Lowers Blood Pressure in Medication-Resistant Hypertension

May 16, 2021 — Two months after undergoing renal denervation (RDN) with the ReCor Paradise renal denervation system ...

May 16, 2021

Etripamil nasal spray was shown in a post-hoc analysis to resolve paroxysmal supraventricular tachycardia faster and more completely than placebo in most patients and reduced the number of emergency room visits for additional interventions.

Feature | EP Lab | By Dave Fornell, Editor

Etripamil Nasal Spray Reduced ER Vistsis and More PSVT Resolution in New NODE-301 Analysis

May 16, 2020 — New data from in the NODE-301 Trial for the patient-administered nasal spray etripamil to resolve ...

May 16, 2021

The Boston Scientific Watchman device have performed better than expected in real-world patients outside of trials since it was introduced in 2015, according to data from the NCDR LAAO Registry. #ACC21 #ACC2021 #LAA #Watchman

Feature | Left Atrial Appendage (LAA) Occluders

NCDR LAAO Registry Shows Left Atrial Appendage Occlusion Associated With Low Rate of Stroke

May 15, 2021 - Transcatheter left atrial appendage occlusion (LAAO) with a Boston Scientific Watchman device was ...

May 16, 2021

The mechanism of action for mavacamten, a cardiac myosin inhibitor to treat obstructive hypertrophic cardiomyopathy (oHCM). EXPLORER-HCM trial #ACC21 #ACC2021

News | Pharmaceuticals

Mavacamten Is Effective in Treating Obstructive Hypertrophic Cardiomyopathy

May 15, 2021 — A new analysis of the Phase 3 EXPLORER-HCM study evaluating mavacamten, an investigational, first-in ...

May 15, 2021

The combination heart failure drug sacubitril/valsartan did not significantly reduce the rate of heart failure or cardiovascular death following a heart attack compared to ramipril, an angiotensin converting enzyme (ACE) inhibitor. #ACC21 #ACC2021

News | Heart Failure

Sacubitril/Valsartan Does Not Outperform ACE Inhibitor in Preventing Heart Failure After Heart Attack

May 15, 2021 — The combination heart failure drug sacubitril/valsartan (Entresto) did not significantly reduce the rate ...

May 15, 2021

In the LAAOS III trial, surgeons could seal off the LAA during the open heart procedure using sutures, staples or approved closure devices. The image shows a SentraHeart lasso type LAA occluder about to seal off the LAA from the outside of the heart. #ACC21 #ACC2021

News | Left Atrial Appendage (LAA) Occluders

Left Atrial Appendage Occlusion Reduces Stroke After Heart Surgery

May 15, 2021 — Patients with an elevated risk of stroke due to heart rhythm problems, or atrial fibrillation (AFib) ...

May 15, 2021

An Edward Lifesciences Sapien TAVR valve during an implant procedure on angiography. There are still questions on how to best anticoagulate TAVR patients and the ATLANTIS study found Eloquis is not a good solution.

News | Structural Heart

TAVR Anticoagulation With Apixaban Not Superior to Standard Care

May 15, 2021 — The anticoagulant apixaban (Eliquis) was not superior to standard of care following transcatheter aortic ...

May 15, 2021

Explaining the Emory TMVR angle. Discordance between mitral annular centerline (yellow lines) and valve orientation imposed by guidewire position within the LV apex (red dashed lines). (B) Valve intrinsic angle (α) is determined by external skirt height. (C) When annular-apical “Emory” angle (red curves) exceeds α (blue curve), annular skirt apposition is not possible, causing PVL (red arrows). (D) The valve is oriented perpendicular to the annual plane using an exteriorized apical guidewire.

Feature | Structural Heart | By Dave Fornell, Editor

The Emory Angle Can Help Eliminate Paravalvular Leak in Transcatheter Mitral Interventions

The mitral valve anatomy is extremely complex, which has caused many challenges for transcatheter mitral valve ...

May 13, 2021